Outlook Therapeutics Announces Upcoming Conference Participation
ISELIN, N.J. — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a leading biopharmaceutical company, is gearing up to participate in the renowned Guggenheim Healthcare Innovation Conference. This event, which promises insightful discussions and networking opportunities, will take place in Boston, with the fireside chat scheduled for November 12, featuring Russell Trenary, President and CEO.
Fireside Chat Details and Management Availability
Trenary will engage in a dynamic fireside chat at 2:30 PM ET, where he will discuss the company’s ongoing efforts and strategies in treating wet age-related macular degeneration (wet AMD) with their innovative product, LYTENAVA™. Furthermore, attendees at the conference will have the chance to meet with the company’s management team for personalized one-on-one discussions.
Live Webcast for Wider Audience
Those unable to attend the event in person will still have the opportunity to access a live webcast of the fireside chat. This webcast will be available on the Events page within the Investors section of the company's website. Preparation to ensure a smooth viewing experience is underway, and the recorded session will be made available for 90 days for those wishing to catch up on the discussions.
About Outlook Therapeutics and Its Innovative Products
Outlook Therapeutics is at the forefront of biopharmaceutical innovation, particularly focusing on the development and commercialization of ONS-5010/LYTENAVA™. This groundbreaking treatment has received regulatory approval for the first-ever ophthalmic formulation of bevacizumab specifically for managing conditions like wet AMD in the European Union and the United Kingdom.
The Path Forward for LYTENAVA™
With the commercial launch of LYTENAVA™ anticipated in the first half of the coming calendar year, Outlook Therapeutics is positioning itself as a pioneer in ocular therapy. The product is expected to provide significant advancements in treating retinal diseases, leveraging cutting-edge science for enhanced patient outcomes.
Research and Development Focus
At present, ONS-5010/LYTENAVA™ is undergoing evaluation in a non-inferiority study in the United States. If results are positive, Outlook Therapeutics plans to resubmit a Biologics License Application (BLA) to the FDA. Approval of this formulation would mark a significant milestone as it could become the first approved ophthalmic formulation of bevacizumab for retinal conditions in the U.S.
Staying Connected with Investors
The communication lines remain open between Outlook Therapeutics and its investor community. Jenene Thomas, the Chief Executive Officer, is the point of contact for investor inquiries, providing insights and fostering relationships that are crucial for the company’s growth trajectory. Interested parties are encouraged to reach out through the provided channels for further discussions on Outlook's innovative approaches in biopharmaceuticals.
Frequently Asked Questions
What is the primary focus of Outlook Therapeutics?
Outlook Therapeutics specializes in the development of treatments for retinal diseases, particularly wet AMD, using advanced biologic formulations.
When will the fireside chat at the Guggenheim Conference take place?
The fireside chat featuring Russell Trenary is scheduled for November 12 at 2:30 PM ET.
Where can I watch the live webcast?
The live webcast of the fireside chat will be accessible on the Events page in the Investors section of Outlook Therapeutics’ website.
What is LYTENAVA™?
LYTENAVA™ is an ophthalmic formulation of bevacizumab approved for treating wet AMD in Europe and the UK.
Who can I contact for investor-related inquiries?
Investor inquiries can be directed to Jenene Thomas, CEO of JTC Team, LLC, at 908.824.0775 or OTLK@jtcir.com.
